CoChat

Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study

Vitek, Jerrold L, Jain, Roshini, Chen, Lilly, Tröster, Alexander I, Schrock, Lauren E, House, Paul A, Giroux, Monique L, Hebb, Adam O, Farris, Sierra M, Whiting, Donald M, Leichliter, Timothy A, Ostrem, Jill L, San Luciano, Marta, Galifianakis, Nicholas, Verhagen Metman, Leo, Sani, Sepehr, Karl, Jessica A, Siddiqui, Mustafa S, Tatter, Stephen B, ul Haq, Ihtsham, Machado, Andre G, Gostkowski, Michal, Tagliati, Michele, Mamelak, Adam N, Okun, Michael S, Foote, Kelly D, Moguel-Cobos, Guillermo, Ponce, Francisco A, Pahwa, Rajesh, Nazzaro, Jules M, Buetefisch, Cathrin M, Gross, Robert E, Luca, Corneliu C, Jagid, Jonathan R, Revuelta, Gonzalo J, Takacs, Istvan, Pourfar, Michael H, Mogilner, Alon Y, Duker, Andrew P, Mandybur, George T, Rosenow, Joshua M, Cooper, Scott E, Park, Michael C, Khandhar, Suketu M, Sedrak, Mark, Phibbs, Fenna T, Pilitsis, Julie G, Uitti, Ryan J, Starr, Philip A · 2020 · The Lancet Neurology
Cited by 153

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND Deep brain stimulation (DBS) of the subthalamic nucleus is an established therapeutic option for managing motor symptoms of Parkinson's disease. We conducted a double-blind, sham-controlled, randomised controlled trial to assess subthalamic nucleus DBS, with a novel multiple independent contact current-controlled (MICC) device, in patients with Parkinson's disease. METHODS This trial took place at 23 implanting centres in the USA. Key inclusion criteria were age between 22 and 75 years, a diagnosis of idiopathic Parkinson's disease with over 5 years of motor symptoms, and stable use of anti-parkinsonian medications for 28 days before consent. Patients who passed screening criteria were implanted with the DBS device bilaterally in the subthalamic nucleus. Patients were randomly assigned in a 3:1 ratio to receive either active therapeutic stimulation settings (active group) or subtherapeutic stimulation settings (control group) for the 3-month blinded period. Randomisation took place with a computer-generated data capture system using a pre-generated randomisation table, stratified by site with random permuted blocks. During the 3-month blinded period, both patients and the assessors were masked to the treatment group while the unmasked programmer was responsible for programming and optimisation of device settings. The primary outcome was the difference in mean change from baseline visit to 3 months post-randomisation between the active and control groups in the mean number of waking hours per day with good symptom control and no troublesome dyskinesias, with no increase in anti-parkinsonian medications. Upon completion of the blinded phase, all patients received active treatment in the open-label period for up to 5 years. Primary and secondary outcomes were analysed by intention to treat. All patients who provided informed consent were included in the safety analysis. The open-label phase is ongoing with no new enrolment, and current findings are based on the prespecified interim analysis of the first 160 randomly assigned patients. The study is registered with ClinicalTrials.gov, NCT01839396. FINDINGS Between May 17, 2013, and Nov 30, 2017, 313 patients were enrolled across 23 sites. Of these 313 patients, 196 (63%) received the DBS implant and 191 (61%) were randomly assigned. Of the 160 patients included in the interim analysis, 121 (76%) were randomly assigned to the active group and 39 (24%) to the control group. The difference in mean change from the baseline visit (post-implant) to 3 months post-randomisation in increased ON time without troublesome dyskinesias between the active and control groups was 3·03 h (SD 4·52, 95% CI 1·3-4·7; p<0·0001). 26 serious adverse events in 20 (13%) patients occurred during the 3-month blinded period. Of these, 18 events were reported in the active group and 8 in the control group. One death was reported among the 196 patients before randomisation, which was unrelated to the procedure, device, or stimulation. INTERPRETATION This double-blind, sham-controlled, randomised controlled trial provides class I evidence of the safety and clinical efficacy of subthalamic nucleus DBS with a novel MICC device for the treatment of motor symptoms of Parkinson's disease. Future trials are needed to investigate potential benefits of producing a more defined current field using MICC technology, and its effect on clinical outcomes. FUNDING Boston Scientific.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(20)30108-3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 153

Metadata

Authors
Vitek, J. L., Jain, R., Chen, L., Tröster, A. I., Schrock, L. E., House, P. A., Giroux, M. L., Hebb, A. O., Farris, S. M., Whiting, D. M., Leichliter, T. A., Ostrem, J. L., San Luciano, M., Galifianakis, N., Verhagen Metman, L., Sani, S., Karl, J. A., Siddiqui, M. S., Tatter, S. B., ul Haq, I., Machado, A. G., Gostkowski, M., Tagliati, M., Mamelak, A. N., Okun, M. S., Foote, K. D., Moguel-Cobos, G., Ponce, F. A., Pahwa, R., Nazzaro, J. M., Buetefisch, C. M., Gross, R. E., Luca, C. C., Jagid, J. R., Revuelta, G. J., Takacs, I., Pourfar, M. H., Mogilner, A. Y., Duker, A. P., Mandybur, G. T., Rosenow, J. M., Cooper, S. E., Park, M. C., Khandhar, S. M., Sedrak, M., Phibbs, F. T., Pilitsis, J. G., Uitti, R. J., & Starr, P. A.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2020-06
Volume
19
Issue
6
Pages
491-501
ISSN
1474-4422 (ISSN-L)
OpenAlex
W3030694699
Cited by
153
References
1
FWCI
7.60
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. https://app.cochat.ai/papers/10.1016/s1474-4422(20)30108-3
The paper
Vitek, J. L., Jain, R., Chen, L., Tröster, A. I., Schrock, L. E., House, P. A., Giroux, M. L., Hebb, A. O., Farris, S. M., Whiting, D. M., Leichliter, T. A., Ostrem, J. L., San Luciano, M., Galifianakis, N., Verhagen Metman, L., Sani, S., Karl, J. A., Siddiqui, M. S., Tatter, S. B., . . . Starr, P. A. (2020). Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(20)30108-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.